According to the FDA, most medical treatments are designed for the “average patient” as a one-size-fits-all-approach, which may be successful for some patients but not for others. The human population shows huge variability to metabolize drugs as the enzymes involved in the process, the cytochrome P450 (CYP-P450) are encoded by 50 or more genes with a range of polymorphism, resulting in either increased or decreased activity. Stemnovate through a compliant liver platform provides research support for studying the genetic difference in the drug transporters, intracellular receptors and the genetically inherited traits that can be a key to new drug development.
Stemnovate offers high-value service contracts with the Pharmaceutical industry to create innovative custom solutions for safety evaluation of drugs candidates in all stages of the drug discovery and development process. We bring together multi-disciplinary areas of microengineering, microfluidics, patented sensor technology, cellular reprogramming and hepatocyte differentiation to create biomimetic liver systems for hepatotoxicity testing and safety screening assays.

Stemnovate’s innovative Liver on-chip technology takes into account variants in the patient’s genetic that enable precision, carefully targeted drug development from the early stages of the process – resulting in safer and more cost-effective drug discovery.

Our platforms facilitate in-depth genomic, transcriptomic and bioinformatic analysis on iPS derived hepatocytes (HLCs) complementing cell line studies to determine the zygosity, cytochrome P450 (CYPs) expression and key pluripotency, hepatic transcripts and membrane transporters within a given population groups complimenting the traditional cell based assays.

FDA is already evaluating ‘on the chip technologies’ for effectiveness for drug discovery , microbiology and toxicology.

Our clients say

You are doing some amazing and important work at Stemnovate, we are happy to be associated with your project.

Volunteer for blood donation for liver research

Thank you for your presentations, they were really great and stimulating. I am very happy we met and that we could get the cells in culture!

Academic Institution
University of Bern


Slippery Liquid-Infused Porous Surfaces: Partnering for Micro-fluidics Smart engineering

Prof Ciro Semprebon will be working in partnership with Stemnovate on the prestigious EPSRC grant project for advancing SLIPS technology.

Partnering for European Space Agency Microgravity Application Promotion Programme

Stemnovate has partnered with multinational collaborators on a project coordinated by MEDES Institute of space medicine and physiology.